{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:27:46Z","timestamp":1793071666203,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Research funding Program","award":["ORF-2025-350"],"award-info":[{"award-number":["ORF-2025-350"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["In Silico Pharmacol."],"DOI":"10.1007\/s40203-026-00639-y","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T03:16:27Z","timestamp":1778469387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Structure-based virtual screening, molecular dynamics and MM-PBSA\/GBSA analysis for the identification of novel CDK6 inhibitors against prostate cancer"],"prefix":"10.1007","volume":"14","author":[{"given":"Manzoor","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ajmal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Zeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishma","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"12","key":"639_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s00894-020-04599-8","volume":"26","author":"M Alazmi","year":"2020","unstructured":"Alazmi M, Motwalli O (2020) Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates. J Mol Model 26(12):338","journal-title":"J Mol Model"},{"issue":"6","key":"639_CR2","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1080\/10406638.2020.1871036","volume":"42","author":"A Atahan","year":"2022","unstructured":"Atahan A (2022) A novel polyaromatic chalcone with multiple functional groups: synthetic, photophysical, and computational elucidation. Polycycl Aromat Compd 42(6):3651\u20133662","journal-title":"Polycycl Aromat Compd"},{"issue":"13","key":"639_CR3","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.7314\/APJCP.2015.16.13.5137","volume":"16","author":"MN Bashir","year":"2015","unstructured":"Bashir MN (2015) Epidemiology of prostate cancer. Asian Pac J Cancer Prev 16(13):5137\u20135141","journal-title":"Asian Pac J Cancer Prev"},{"issue":"24","key":"639_CR4","doi-asserted-by":"publisher","first-page":"6164","DOI":"10.3390\/cancers14246164","volume":"14","author":"J Bas\u00edlio","year":"2022","unstructured":"Bas\u00edlio J et al (2022) Antagonistic functions of androgen receptor and NF-\u03baB in prostate cancer\u2014experimental and computational analyses. Cancers 14(24):6164","journal-title":"Cancers"},{"issue":"48","key":"639_CR5","doi-asserted-by":"publisher","first-page":"33770","DOI":"10.1039\/D3RA05672D","volume":"13","author":"BK Chagaleti","year":"2023","unstructured":"Chagaleti BK et al (2023) Exploring cyclin-dependent kinase inhibitors: a comprehensive study in search of CDK-6 inhibitors using a pharmacophore modelling and dynamics approach. RSC Adv 13(48):33770\u201333785","journal-title":"RSC Adv"},{"issue":"1","key":"639_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40001-022-00730-y","volume":"27","author":"X Chen","year":"2022","unstructured":"Chen X et al (2022) CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer. Eur J Med Res 27(1):105","journal-title":"Eur J Med Res"},{"issue":"4","key":"639_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30040805","volume":"30","author":"J Chen","year":"2025","unstructured":"Chen J et al (2025) Identifying Inhibitor-SARS-CoV2-3CLpro binding mechanism through molecular docking, GaMD simulations, correlation network analysis and MM-GBSA calculations. Molecules 30(4):805","journal-title":"Molecules"},{"key":"639_CR8","doi-asserted-by":"crossref","unstructured":"Coleman WB (2018) Molecular pathogenesis of prostate cancer. In: Molecular pathology. Elsevier, pp 555\u2013568","DOI":"10.1016\/B978-0-12-802761-5.00025-0"},{"issue":"3","key":"639_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/jcb.10747","volume":"91","author":"AM De Marzo","year":"2004","unstructured":"De Marzo AM et al (2004) Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 91(3):459\u2013477","journal-title":"J Cell Biochem"},{"issue":"21","key":"639_CR10","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.1021\/jm100387d","volume":"53","author":"G Dong","year":"2010","unstructured":"Dong G et al (2010) Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents. J Med Chem 53(21):7521\u20137531","journal-title":"J Med Chem"},{"issue":"2","key":"639_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1110000","volume":"366","author":"CM Ewing","year":"2012","unstructured":"Ewing CM et al (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366(2):141\u2013149","journal-title":"N Engl J Med"},{"key":"639_CR12","doi-asserted-by":"crossref","unstructured":"Folkmanis K et al (2021) Current trends in prostate cancer etiology, pathogenesis and diagnostics. In: Proceedings of the Latvian academy of sciences. De Gruyter Poland","DOI":"10.2478\/prolas-2021-0048"},{"issue":"1","key":"639_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41391-017-0023-8","volume":"21","author":"J Gandhi","year":"2018","unstructured":"Gandhi J et al (2018) The molecular biology of prostate cancer: current understanding and clinical implications. Prostate Cancer Prostatic Dis 21(1):22\u201336","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"639_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10(5):449\u2013461","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"639_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75292-6","volume":"14","author":"D Gheidari","year":"2024","unstructured":"Gheidari D, Mehrdad M, Karimelahi Z (2024) Virtual screening, ADMET prediction, molecular docking, and dynamic simulation studies of natural products as BACE1 inhibitors for the management of Alzheimer\u2019s disease. Sci Rep 14(1):26431","journal-title":"Sci Rep"},{"issue":"2","key":"639_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jics.2022.100339","volume":"99","author":"P Gopinath","year":"2022","unstructured":"Gopinath P, Kathiravan M (2022) Molecular insights of oxadiazole benzene sulfonamides as human carbonic anhydrase IX inhibitors: combined molecular docking, molecular dynamics, and 3D QSAR studies. J Indian Chem Soc 99(2):100339","journal-title":"J Indian Chem Soc"},{"issue":"1","key":"639_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/ci100275a","volume":"51","author":"T Hou","year":"2011","unstructured":"Hou T et al (2011) Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 51(1):69\u201382","journal-title":"J Chem Inf Model"},{"issue":"37","key":"639_CR18","doi-asserted-by":"publisher","first-page":"e01592","DOI":"10.1002\/slct.202501592","volume":"10","author":"A Iqbal","year":"2025","unstructured":"Iqbal A et al (2025) Comprehensive computational and in vivo approaches to assess the analgesic activity of the selected flavonoids from the maclura plant against the Mu-opioid receptor. ChemistrySelect 10(37):e01592","journal-title":"ChemistrySelect"},{"issue":"19","key":"639_CR19","doi-asserted-by":"publisher","first-page":"9695","DOI":"10.1080\/07391102.2022.2145497","volume":"41","author":"BP Joshi","year":"2023","unstructured":"Joshi BP et al (2023) Friedelin, a novel inhibitor of CYP17A1 in prostate cancer from Cassia tora. J Biomol Struct Dynamics 41(19):9695\u20139720","journal-title":"J Biomol Struct Dynamics"},{"key":"639_CR20","doi-asserted-by":"publisher","first-page":"10499","DOI":"10.2147\/OTT.S266085","volume":"13","author":"AM Kase","year":"2020","unstructured":"Kase AM, Copland JA, Tan W (2020) Novel therapeutic strategies for CDK4\/6 inhibitors in metastatic castrate-resistant prostate cancer. Onco Targets Ther 13:10499\u201310513","journal-title":"Onco Targets Ther"},{"issue":"8","key":"639_CR21","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1080\/07391102.2023.2300121","volume":"43","author":"M Khan","year":"2025","unstructured":"Khan M et al (2025) Computational exploration of allosteric inhibitors targeting CDK4\/CDK6 proteins: a promising approach for multi-target drug development. J Biomol Struct Dyn 43(8):3783\u20133801","journal-title":"J Biomol Struct Dyn"},{"issue":"1","key":"639_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/cancers15010149","volume":"15","author":"S Koivusalo","year":"2022","unstructured":"Koivusalo S et al (2022) Regulation of kinase signaling pathways by \u03b16\u03b24-integrins and plectin in prostate cancer. Cancers 15(1):149","journal-title":"Cancers"},{"key":"639_CR23","volume-title":"Computational investigation of calcium binding proteins annexin A1 and cardiac troponin C","author":"KA Lewis","year":"2019","unstructured":"Lewis KA (2019) Computational investigation of calcium binding proteins annexin A1 and cardiac troponin C. East Carolina University"},{"issue":"6","key":"639_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00432-024-05818-y","volume":"150","author":"J-D Liang","year":"2024","unstructured":"Liang J-D et al (2024) Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl) pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2\/4\/6. J Cancer Res Clin Oncol 150(6):302","journal-title":"J Cancer Res Clin Oncol"},{"key":"639_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcab.2025.103556","volume":"65","author":"Y Mamatha","year":"2025","unstructured":"Mamatha Y et al (2025) Identification of natural compounds as inhibitors of clumping factor A in Staphylococcus aureus to combat bovine mastitis: an in-silico approach. Biocatal Agric Biotechnol 65:103556","journal-title":"Biocatal Agric Biotechnol"},{"issue":"5","key":"639_CR26","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1007\/s11030-022-10395-8","volume":"26","author":"S Manandhar","year":"2022","unstructured":"Manandhar S et al (2022) Molecular dynamics and structure-based virtual screening and identification of natural compounds as Wnt signaling modulators: possible therapeutics for Alzheimer\u2019s disease. Mol Divers 26(5):2793\u20132811","journal-title":"Mol Divers"},{"key":"639_CR27","doi-asserted-by":"crossref","unstructured":"Mbatha SZ (2024) Understanding prostate cancer: pathogenesis, risk factors, and early detection. In: Transforming prostate cancer care: advancing cancer treatment with Insights from Africa. Springer, pp 27\u201343","DOI":"10.1007\/978-3-031-64388-0_2"},{"key":"639_CR28","doi-asserted-by":"publisher","first-page":"127891","DOI":"10.1016\/j.molstruc.2020.127891","volume":"1208","author":"A Mermer","year":"2020","unstructured":"Mermer A et al (2020) Synthesis, DFT calculations, biological investigation, molecular docking studies of \u03b2-lactam derivatives. J Mol Struct 1208:127891","journal-title":"J Mol Struct"},{"issue":"34","key":"639_CR29","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.1021\/acs.jpcb.8b03655","volume":"122","author":"SK Mishra","year":"2018","unstructured":"Mishra SK, Ko\u010da J (2018) Assessing the performance of MM\/PBSA, MM\/GBSA, and QM\u2013MM\/GBSA approaches on protein\/carbohydrate complexes: effect of implicit solvent models, QM methods, and entropic contributions. J Phys Chem B 122(34):8113\u20138121","journal-title":"J Phys Chem B"},{"issue":"2","key":"639_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/156800909787580999","volume":"9","author":"TM Morgan","year":"2009","unstructured":"Morgan TM, Koreckij TD, Corey E (2009) Targeted therapy for advanced prostate cancer: inhibition of the PI3K\/Akt\/mTOR pathway. Curr Cancer Drug Targets 9(2):237\u2013249","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"639_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00894-021-04750-z","volume":"27","author":"O Motwalli","year":"2021","unstructured":"Motwalli O, Alazmi M (2021) Analysis of natural compounds against the activity of SARS-CoV-2 NSP15 protein towards an effective treatment against COVID-19: a theoretical and computational biology approach. J Mol Model 27(6):160","journal-title":"J Mol Model"},{"key":"639_CR32","doi-asserted-by":"crossref","unstructured":"Murray TB (2021) The pathogenesis of prostate cancer. Exon Publ 29\u201341","DOI":"10.36255\/exonpublications.prostatecancer.pathogenesis.2021"},{"issue":"5","key":"639_CR33","first-page":"S6","volume":"172","author":"WG Nelson","year":"2004","unstructured":"Nelson WG et al (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172(5):S6\u2013S12","journal-title":"J Urol"},{"issue":"12","key":"639_CR34","doi-asserted-by":"publisher","first-page":"a030361","DOI":"10.1101\/cshperspect.a030361","volume":"8","author":"CH Pernar","year":"2018","unstructured":"Pernar CH et al (2018) The Epidemiology of prostate cancer. Cold Spring Harb Perspect Med 8(12):a030361","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"639_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63\u201389","journal-title":"World J Oncol"},{"issue":"23","key":"639_CR36","doi-asserted-by":"publisher","first-page":"14358","DOI":"10.1080\/07391102.2023.2187638","volume":"41","author":"A Raza","year":"2023","unstructured":"Raza A et al (2023) Molecular modeling of pyrrolo-pyrimidine based analogs as potential FGFR1 inhibitors: a scientific approach for therapeutic drugs. J Biomol Struct Dynamics 41(23):14358\u201314371","journal-title":"J Biomol Struct Dynamics"},{"key":"639_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jmgm.2014.03.001","volume":"50","author":"W Sangpheak","year":"2014","unstructured":"Sangpheak W et al (2014) Enhanced stability of a naringenin\/2, 6-dimethyl \u03b2-cyclodextrin inclusion complex: molecular dynamics and free energy calculations based on MM-and QM-PBSA\/GBSA. J Mol Graph Model 50:10\u201315","journal-title":"J Mol Graph Model"},{"key":"639_CR38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3389\/fonc.2018.00608","volume":"8","author":"F Schettini","year":"2018","unstructured":"Schettini F et al (2018) CDK 4\/6 inhibitors as single agent in advanced solid tumors. Front Oncol 8:608\u2013608","journal-title":"Front Oncol"},{"issue":"1\u20132","key":"639_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jsbmb.2011.01.016","volume":"125","author":"D Schuster","year":"2011","unstructured":"Schuster D et al (2011) Identification of chemically diverse, novel inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening. J Steroid Biochem Mol Biol 125(1\u20132):148\u2013161","journal-title":"J Steroid Biochem Mol Biol"},{"key":"639_CR40","doi-asserted-by":"publisher","first-page":"1537872","DOI":"10.3389\/fcimb.2025.1537872","volume":"15","author":"M Shah","year":"2025","unstructured":"Shah M et al (2025) Computational analysis of ayurvedic metabolites for potential treatment of drug-resistant Candida auris. Front Cell Infect Microbiol 15:1537872","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"639_CR41","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijms21124507","volume":"21","author":"BY Shorning","year":"2020","unstructured":"Shorning BY et al (2020) The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci 21(12):4507","journal-title":"Int J Mol Sci"},{"issue":"1","key":"639_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-025-10531-1","volume":"52","author":"MK Sivo\u0148ov\u00e1","year":"2025","unstructured":"Sivo\u0148ov\u00e1 MK et al (2025) Genetic alterations of Cyclin D-CDK4\/6-INK4-RB pathway in prostate cancer. Mol Biol Rep 52(1):1\u201310","journal-title":"Mol Biol Rep"},{"issue":"23","key":"639_CR43","doi-asserted-by":"publisher","first-page":"9496","DOI":"10.1021\/jm400870h","volume":"56","author":"V Sorna","year":"2013","unstructured":"Sorna V et al (2013) High-throughput virtual screening identifies novel N\u2032-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. J Med Chem 56(23):9496\u20139508","journal-title":"J Med Chem"},{"issue":"24","key":"639_CR44","doi-asserted-by":"publisher","first-page":"13423","DOI":"10.3390\/ijms222413423","volume":"22","author":"NMP Susanti","year":"2021","unstructured":"Susanti NMP et al (2021) A search for cyclin-dependent kinase 4\/6 inhibitors by pharmacophore-based virtual screening, molecular docking, and molecular dynamic simulations. Int J Mol Sci 22(24):13423","journal-title":"Int J Mol Sci"},{"issue":"1","key":"639_CR45","doi-asserted-by":"publisher","first-page":"23505","DOI":"10.1038\/s41598-024-71865-7","volume":"14","author":"NMP Susanti","year":"2024","unstructured":"Susanti NMP et al (2024) The novel selective inhibitors of cyclin-dependent kinase 4\/6: in vitro and in silico study. Sci Rep 14(1):23505","journal-title":"Sci Rep"},{"issue":"3","key":"639_CR46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/medicines6030082","volume":"6","author":"U Testa","year":"2019","unstructured":"Testa U, Castelli G, Pelosi E (2019) Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications. Medicines 6(3):82","journal-title":"Medicines"},{"issue":"4","key":"639_CR47","first-page":"213","volume":"8","author":"V Velcheti","year":"2008","unstructured":"Velcheti V et al (2008) Pathogenesis of prostate cancer: lessons from basic research. Ochsner J 8(4):213\u2013218","journal-title":"Ochsner J"},{"issue":"16","key":"639_CR48","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","volume":"119","author":"E Wang","year":"2019","unstructured":"Wang E et al (2019) End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design. Chem Rev 119(16):9478\u20139508","journal-title":"Chem Rev"},{"key":"639_CR49","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ijbiomac.2022.06.013","volume":"213","author":"M Yousuf","year":"2022","unstructured":"Yousuf M et al (2022) Naringenin as a potential inhibitor of human cyclin-dependent kinase 6: molecular and structural insights into anti-cancer therapeutics. Int J Biol Macromol 213:944\u2013954","journal-title":"Int J Biol Macromol"},{"issue":"11","key":"639_CR50","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.3390\/biomedicines11113078","volume":"11","author":"AF Zahoor","year":"2023","unstructured":"Zahoor AF et al (2023) Synthesis, cytotoxic, and computational screening of some novel indole-1, 2, 4-triazole-based S-alkylated N-aryl acetamides. Biomedicines 11(11):3078","journal-title":"Biomedicines"}],"container-title":["In Silico Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40203-026-00639-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40203-026-00639-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40203-026-00639-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:03:37Z","timestamp":1778493817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40203-026-00639-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["639"],"URL":"https:\/\/doi.org\/10.1007\/s40203-026-00639-y","relation":{},"ISSN":["2193-9616"],"issn-type":[{"value":"2193-9616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal activities (using mice) in the study were approved by the institutional Ethical. Committee of Abasyn University, under approval number (Ref. No. IERC-AUP 2024-013) on 25 July 2024.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"140"}}